💼InvestingCG Oncology Fair Value Revised Following Phase 3 Clinical Results
Recent Phase 3 clinical data for CG Oncology's bladder cancer treatment has prompted a reevaluation of the company's stock, though analysts see limited room for further n…
💼InvestingRecent Phase 3 clinical data for CG Oncology's bladder cancer treatment has prompted a reevaluation of the company's stock, though analysts see limited room for further n…
Got a tip, a proposal or a partnership question? Write to us and we will reply shortly.